# Medpace Holdings, Inc.: financial statements, quarterly

MEDP · Nasdaq · CIK 1668397 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/medp.md) · [Financials](/companies/medp/financials.md) · [Filings](/companies/medp/filings.md) · [Insiders](/companies/medp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/medp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [498 d](/filings/0001668397-26-000006.md) | [511](/filings/0001668397-25-000059.md) | [528](/filings/0001668397-25-000087.md) | [533](/filings/0001668397-25-000110.md) | [537 d](/filings/0001668397-26-000006.md) | [559](/filings/0001668397-26-000019.md) | [603](/filings/0001668397-26-000025.md) | [660](/filings/0001668397-26-000036.md) | [708 d](/filings/0001668397-26-000006.md) | [707](/filings/0001668397-26-000019.md) | [707](/filings/0001668397-26-000025.md) | [716](/filings/0001668397-26-000036.md) |
| Selling, general and administrative | $m | [42.5 d](/filings/0001668397-26-000006.md) | [44.1](/filings/0001668397-25-000059.md) | [41.5](/filings/0001668397-25-000087.md) | [49.2](/filings/0001668397-25-000110.md) | [45.4 d](/filings/0001668397-26-000006.md) | [57.9](/filings/0001668397-26-000019.md) | [46.7](/filings/0001668397-26-000025.md) | [48.1](/filings/0001668397-26-000036.md) | [44.9 d](/filings/0001668397-26-000006.md) | [47.9](/filings/0001668397-26-000019.md) | [48.1](/filings/0001668397-26-000025.md) | [51.8](/filings/0001668397-26-000036.md) |
| Operating income | $m | [87.3 d](/filings/0001668397-26-000006.md) | [104](/filings/0001668397-25-000059.md) | [105](/filings/0001668397-25-000087.md) | [112](/filings/0001668397-25-000110.md) | [125 d](/filings/0001668397-26-000006.md) | [114](/filings/0001668397-26-000019.md) | [126](/filings/0001668397-26-000025.md) | [142](/filings/0001668397-26-000036.md) | [153 d](/filings/0001668397-26-000006.md) | [142](/filings/0001668397-26-000019.md) | [147](/filings/0001668397-26-000025.md) | [166](/filings/0001668397-26-000036.md) |
| Income tax | $m | [12.4 d](/filings/0001668397-26-000006.md) | [10.2](/filings/0001668397-25-000059.md) | [22.1](/filings/0001668397-25-000087.md) | [22.4](/filings/0001668397-25-000110.md) | [16.9 d](/filings/0001668397-26-000006.md) | [3.6](/filings/0001668397-26-000019.md) | [34.3](/filings/0001668397-26-000025.md) | [31.7](/filings/0001668397-26-000036.md) | [21.7 d](/filings/0001668397-26-000006.md) | [23.7](/filings/0001668397-26-000019.md) | [30.3](/filings/0001668397-26-000025.md) | [33.4](/filings/0001668397-26-000036.md) |
| Net income | $m | [78.3 d](/filings/0001668397-26-000006.md) | [103](/filings/0001668397-25-000110.md) | [88.4](/filings/0001668397-25-000110.md) | [96.4](/filings/0001668397-25-000110.md) | [117 d](/filings/0001668397-26-000006.md) | [115](/filings/0001668397-26-000036.md) | [90.3](/filings/0001668397-26-000036.md) | [111](/filings/0001668397-26-000036.md) | [135 d](/filings/0001668397-26-000006.md) | [124](/filings/0001668397-26-000036.md) | [121](/filings/0001668397-26-000036.md) | [137](/filings/0001668397-26-000036.md) |
| Diluted EPS | $ per share | not reported | [3.20](/filings/0001668397-25-000059.md) | [2.75](/filings/0001668397-25-000087.md) | [3.01](/filings/0001668397-25-000110.md) | not reported | [3.67](/filings/0001668397-26-000019.md) | [3.10](/filings/0001668397-26-000025.md) | [3.86](/filings/0001668397-26-000036.md) | not reported | [4.28](/filings/0001668397-26-000019.md) | [4.25](/filings/0001668397-26-000025.md) | [4.84](/filings/0001668397-26-000036.md) |
| Basic EPS | $ per share | not reported | [3.32](/filings/0001668397-25-000059.md) | [2.85](/filings/0001668397-25-000087.md) | [3.11](/filings/0001668397-25-000110.md) | not reported | [3.77](/filings/0001668397-26-000019.md) | [3.16](/filings/0001668397-26-000025.md) | [3.95](/filings/0001668397-26-000036.md) | not reported | [4.35](/filings/0001668397-26-000019.md) | [4.31](/filings/0001668397-26-000025.md) | [4.92](/filings/0001668397-26-000036.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [245](/filings/0001668397-25-000017.md) | [407](/filings/0001668397-24-000091.md) | [511](/filings/0001668397-24-000143.md) | [657](/filings/0001668397-24-000168.md) | [669](/filings/0001668397-26-000006.md) | [441](/filings/0001668397-25-000059.md) | [46.3](/filings/0001668397-25-000087.md) | [285](/filings/0001668397-25-000110.md) | [497](/filings/0001668397-26-000036.md) | [653](/filings/0001668397-26-000019.md) | [503](/filings/0001668397-26-000025.md) | [705](/filings/0001668397-26-000036.md) |
| Current assets | $m | [594](/filings/0001668397-25-000017.md) | [745](/filings/0001668397-24-000091.md) | [873](/filings/0001668397-24-000143.md) | [1,033](/filings/0001668397-24-000168.md) | [1,029](/filings/0001668397-26-000006.md) | [821](/filings/0001668397-25-000059.md) | [521](/filings/0001668397-25-000087.md) | [737](/filings/0001668397-25-000110.md) | [990](/filings/0001668397-26-000036.md) | [1,139](/filings/0001668397-26-000019.md) | [1,050](/filings/0001668397-26-000025.md) | [1,245](/filings/0001668397-26-000036.md) |
| Total assets | $m | [1,657](/filings/0001668397-25-000017.md) | [1,796](/filings/0001668397-24-000091.md) | [1,920](/filings/0001668397-24-000143.md) | [2,084](/filings/0001668397-24-000168.md) | [2,101](/filings/0001668397-26-000006.md) | [1,897](/filings/0001668397-25-000059.md) | [1,572](/filings/0001668397-25-000087.md) | [1,753](/filings/0001668397-25-000110.md) | [1,975](/filings/0001668397-26-000036.md) | [2,130](/filings/0001668397-26-000019.md) | [2,057](/filings/0001668397-26-000025.md) | [2,303](/filings/0001668397-26-000036.md) |
| Current liabilities | $m | [925](/filings/0001668397-25-000017.md) | [957](/filings/0001668397-24-000091.md) | [993](/filings/0001668397-24-000143.md) | [1,041](/filings/0001668397-24-000168.md) | [1,105](/filings/0001668397-26-000006.md) | [1,122](/filings/0001668397-25-000059.md) | [1,220](/filings/0001668397-25-000087.md) | [1,284](/filings/0001668397-25-000110.md) | [1,344](/filings/0001668397-26-000036.md) | [1,345](/filings/0001668397-26-000019.md) | [1,435](/filings/0001668397-26-000025.md) | [1,496](/filings/0001668397-26-000036.md) |
| Total liabilities | $m | [1,098](/filings/0001668397-25-000017.md) | [1,124](/filings/0001668397-24-000091.md) | [1,156](/filings/0001668397-24-000143.md) | [1,203](/filings/0001668397-24-000168.md) | [1,275](/filings/0001668397-26-000006.md) | [1,304](/filings/0001668397-25-000059.md) | [1,399](/filings/0001668397-25-000087.md) | [1,459](/filings/0001668397-25-000110.md) | [1,516](/filings/0001668397-26-000036.md) | [1,531](/filings/0001668397-26-000019.md) | [1,623](/filings/0001668397-26-000025.md) | [1,718](/filings/0001668397-26-000036.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0001668397-24-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [559](/filings/0001668397-26-000006.md) | [672](/filings/0001668397-25-000110.md) | [764](/filings/0001668397-25-000110.md) | [881](/filings/0001668397-25-000110.md) | [826](/filings/0001668397-26-000036.md) | [594](/filings/0001668397-26-000036.md) | [172](/filings/0001668397-26-000036.md) | [294](/filings/0001668397-26-000036.md) | [459](/filings/0001668397-26-000036.md) | [598](/filings/0001668397-26-000036.md) | [434](/filings/0001668397-26-000036.md) | [585](/filings/0001668397-26-000036.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [156 d](/filings/0001668397-26-000006.md) | [153](/filings/0001668397-25-000059.md) | [116 d](/filings/0001668397-25-000087.md) | [149 d](/filings/0001668397-25-000110.md) | [191 d](/filings/0001668397-26-000006.md) | [126](/filings/0001668397-26-000019.md) | [149 d](/filings/0001668397-26-000025.md) | [246 d](/filings/0001668397-26-000036.md) | [193 d](/filings/0001668397-26-000006.md) | [152](/filings/0001668397-26-000019.md) | [162 d](/filings/0001668397-26-000025.md) | [217 d](/filings/0001668397-26-000036.md) |
| Capital expenditure | $m | [10.0 d](/filings/0001668397-26-000006.md) | [5.5](/filings/0001668397-25-000059.md) | [12.9 d](/filings/0001668397-25-000087.md) | [10.5 d](/filings/0001668397-25-000110.md) | [7.6 d](/filings/0001668397-26-000006.md) | [10.0](/filings/0001668397-26-000019.md) | [6.1 d](/filings/0001668397-26-000025.md) | [10.7 d](/filings/0001668397-26-000036.md) | [4.5 d](/filings/0001668397-26-000006.md) | [6.8](/filings/0001668397-26-000019.md) | [23.9 d](/filings/0001668397-26-000025.md) | [20.2 d](/filings/0001668397-26-000036.md) |
| Share repurchases | $m | [0.0 d](/filings/0001668397-26-000006.md) | [0.0](/filings/0001668397-25-000059.md) | [0.0 d](/filings/0001668397-25-000087.md) | [0.0 d](/filings/0001668397-25-000110.md) | [170 d](/filings/0001668397-26-000006.md) | [372](/filings/0001668397-26-000019.md) | [541 d](/filings/0001668397-26-000025.md) | [4.6 d](/filings/0001668397-26-000036.md) | [0.0 d](/filings/0001668397-26-000006.md) | [0.0](/filings/0001668397-26-000019.md) | [295 d](/filings/0001668397-26-000025.md) | [0.0 d](/filings/0001668397-26-000036.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.2](/filings/0001668397-24-000091.md) | [31.6](/filings/0001668397-24-000143.md) | [31.8](/filings/0001668397-24-000168.md) | [32.0](/filings/0001668397-25-000059.md) | [32.1](/filings/0001668397-25-000087.md) | [32.1](/filings/0001668397-25-000110.md) | [31.2](/filings/0001668397-26-000019.md) | [29.1](/filings/0001668397-26-000025.md) | [28.8](/filings/0001668397-26-000036.md) | [29.0](/filings/0001668397-26-000019.md) | [28.6](/filings/0001668397-26-000025.md) | [28.4](/filings/0001668397-26-000036.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,971,686 at 2026-10-16, from the cover of the [10-Q filed 2026-10-22](/filings/0001668397-26-000036.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.